Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Meningiomas

Therapeutic options for recurrent or metastatic tumors

    • Congress Reports
    • Neurology
    • Oncology
    • RX
    • Studies
  • 4 minute read

A “Special Session” at the ESMO Congress focused on meningiomas. Although these brain tumors are primarily treated surgically, higher-grade meningiomas that can grow invasively may require radio or systems therapy.

(ee) An introduction to the classification and molecular pathology of meningiomas was given by Prof. Christian Mawrin, MD, director of the Institute of Neuropathology at Otto von Guericke University Magdeburg, Germany. Meningiomas are the most common intracranial tumors: they account for 54% of all benign brain tumors, but also 1% of all malignant brain tumors. Women are two to three times more likely to be affected by meningiomas than men.

About 80% of meningiomas belong to the grade I tumor group, 20% correspond to grade II (atypical meningiomas), and less than 1% are grade III anaplastic tumors. The prognosis of meningioma disease is usually good, but grade II and grade III meningiomas in particular are associated with significant morbidity and mortality. Recurrent meningiomas are at risk for invasive growth. A whole range of pathological subtypes are distinguished, e.g. angiomatous, fibromatous and secretory meningiomas of grade I.

Classification according to Simpson grades

Based on the observation that patients with neurofibromatosis type 2 (NR2) frequently develop meningiomas, loss of the NF2 gene on chromosome 22q has been identified as the major genetic alteration leading to meningioma development. NF2 alterations are found in 40-50% of all sporadic meningiomas, and in the mouse model it has been shown that loss of NF2 is the initial step in the development of meningiomas. Progression of grade I meningioma to a more aggressive form is linked to inactivation of suppressor genes. In particular, alterations of the CDKN2A/CDKN2B genes on chromosome 9p play an important role.

Very important in the evaluation of meningiomas is the location: meningiomas in the convexity are more likely to have NF2 alterations, and meningiomas at the skull base, which recur more often than meningiomas of the convexity, are more often of the NF2 wild type.

After resection, meningiomas are graded according to the Simpson grading system (Tab. 1) . This dates back to 1957 and is still up to date! The grading is important for assessing the risk of recurrence: this is about 10% for Simpson 1, about 20% for Simpson 2, and even greater for higher Simpson grades.

Radiotherapy for meningiomas

Prof. Damien Weber, MD, Chief Physician of the Center for Proton Therapy, Paul Scherrer Institute, Villigen, provided information on the possibilities of radiotherapy. Meningiomas were once considered resistant to radiation, but radiotherapy is now considered an effective adjuvant treatment. For meningiomas of grade I and a Simpson resection ≥3, radiation after surgery improves tumor control. However, it is not yet clear when radiation should be given, i.e., whether immediately postoperatively or only at progression, and at what dosage. For this reason, the EORTC started a corresponding study in 2004.

For higher-grade meningiomas, most retreospective studies show better efficacy of radiotherapy at higher doses. For this reason, the EORTC is investigating adjuvant, postoperative high-dose radiotherapy for non-benign meningiomas in a phase II trial. Patients with incomplete resection (Simpson ≥3) are irradiated with 70 Gy. First results are expected in 2016.

Also open is the question of whether to irradiate grade II meningiomas after complete resection (Simpson 1). Several studies show that the recurrence rate is greater in unirradiated patients than in patients who received radiotherapy. However, radiotherapy is not recommended in most centers.

In a currently ongoing study by the Radiation Therapy Oncology Group (RTOG), patients are divided into three risk groups: Low-risk patients (WHO grade I, all Simpson grades) are observed but not irradiated; intermediate-risk patients (WHO grade II, Simpson ≤3; WHO grade I with recurrence) receive radiotherapy at 54 Gy; high-risk patients (all others) receive radiotherapy at 60 Gy. Results are currently pending.

Systemic therapy

Recurrent, progressive or metastatic meningiomas can no longer be treated with surgery or radiotherapy, explained Prof. Matthias Preusser, MD, Medical University of Vienna. To date, there have been few studies of systemic therapies, and little is known about biomarkers and targets. The few existing data on targeted agents come mostly from case reports, smaller uncontrolled studies, and retrospective analyses. To date, no benefit of interferon-alpha, octreotide analogues, mifepristone, megestrol acetate, imatinib, erlotinib, or gefitinib has been demonstrated. Possibly effective substances are:

  • Bevacizumab; It shows low response rates in smaller studies. Currently, the use of bevacizumab in meningiomas is being investigated in two studies.
  • Sunitinib, a tyrosine kinase inhibitor, showed efficacy in a recent phase II trial in 36 patients with high-grade meningiomas and multiple recurrences [1]. 42% of patients were still progression-free six months after therapy (primary endpoint). Based on these results, the authors propose to conduct a randomized trial.
  • A Phase II trial of vatalinib, another tyrosine kinase inhibitor, was also recently completed.
  • Trabectedin (Yondelis®), an active ingredient derived from a sea squirt (tunicate), is already approved for the treatment of sarcoma and ovarian cancer. Further studies are underway on several other tumors. Following a promising in vitro study, an EORTC trial is now starting in 2015 in more than 30 centers in Europe in patients suffering from recurrent grade II or III meningioma who have run out of local treatment options.

Source: European Society for Medical Oncology (ESMO) Congress, September 26-30, 2014, Madrid.

Literature:

  1. Kaley T, et al: Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro-Oncology 2014; 0: 1-6.

InFo ONCOLOGY & HEMATOLOGY 2014; 2(9): 27-28.

Autoren
  • Dr. med. Eva Ebnöther
Publikation
  • InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
  • bevacizumab
  • Brain tumor
  • Brain tumor
  • CDKN2A
  • Meningioma
  • NR2
  • RTOG
  • Simpson
  • Sunitinib
  • Trabectedin
  • Vatalinib
Previous Article
  • Generalized anxiety disorder

Is GAD too rarely recognized?

  • Congress Reports
  • News
  • Psychiatry and psychotherapy
  • RX
View Post
Next Article
  • Specific oncological and social problems

Cancer in young adults: Experts call for treatment protocols

  • Congress Reports
  • Oncology
  • Pediatrics
  • RX
View Post
You May Also Like
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 4 min
  • Plea for sex-specific neurology

Migraine in men: underdiagnosed, underestimated, under-researched

    • Education
    • Neurology
    • RX
    • Studies
View Post
  • 4 min
  • Prurigo nodularis

Retrospective analyses of large data sets from everyday practice

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.